Jefferies reiterates Buy rating on Travere Therapeutics stock with $35 target

Travere Therapeutics (NASDAQ:TVTX) received a significant boost as the FDA canceled its advisory committee meeting for the company's FSGS indication, which analysts, including Jefferies (maintaining Buy, $35 PT), interpret as strong FDA support for UPCR as a primary endpoint and potential for approval ahead of the January 13, 2026 PDUFA date. This development, alongside FDA-approved reduced monitoring for FILSPARI in IgA nephropathy and positive long-term data for its pegtibatinase candidate, has driven TVTX shares up over 10% in the past week, trading near its 52-week high. Other firms like Cantor Fitzgerald and H.C. Wainwright also reiterated positive ratings, underscoring broad analyst confidence.

Analysis

Travere Therapeutics (TVTX) has experienced a significant positive regulatory development with the FDA's cancellation of an advisory committee meeting for its focal segmental glomerulosclerosis (FSGS) indication. This event is interpreted by analysts, including Jefferies, as a strong signal of the FDA's support for using UPCR as the primary endpoint for full approval, substantially de-risking the path forward. While the official PDUFA date remains January 13, 2026, the analyst commentary suggests a potential for accelerated approval. This news, coupled with other positive developments such as the FDA's approval of reduced monitoring for FILSPARI and promising long-term data for its pegtibatinase candidate, has fueled broad analyst confidence. Firms like Jefferies, Cantor Fitzgerald, and H.C. Wainwright have reiterated 'Buy' or 'Overweight' ratings, with price targets set at $35.00 and $47.00, respectively. The market has reacted strongly, with the stock gaining 10.35% over the past week and trading near its 52-week high of $27.31.

Key Decisions for Investors

• Investors should view the cancellation of the FDA advisory committee meeting as a significant de-risking event for the FSGS indication, reinforcing the bullish analyst consensus.
• Consider the potential for further upside, as analyst price targets of $35.00 and $47.00 suggest significant room for appreciation from the current trading price.
• Monitor for any company or FDA communications that could indicate an accelerated approval timeline ahead of the January 13, 2026 PDUFA date, as this would serve as a major near-term catalyst.
• Although momentum is strong, the stock is trading near its 52-week high after a 10.35% weekly gain, so prudent investors may wish to assess valuation and entry points carefully.